Stock Region Penny Picks
Stock Region Penny Picks Watchlist Newsletter - Thursday, July 31, 2025.
Stock Region Penny Picks Watchlist Newsletter - Thursday, July 31, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is for informational purposes only and is not financial advice. Always consult with a professional before making investment decisions. Stocks mentioned may carry risk, and past performance does not guarantee future results.
Hi Stock Region fam,
Are you ready for today’s deep dive into the market movers and shakers? There’s plenty to unpack, from biotech breakthroughs to stellar earnings reports. Here’s what caught our attention today and why you might want to keep these stocks on your radar.
🚚 $VRME - Verimatrix Teams Up with UPS
Big news here! Verimatrix secured a 3-year agreement with UPS to support its Digital Channel Program. Partnering with a logistics giant like UPS is no small feat. This move could significantly enhance $VRME’s reach and revenue streams. We’re intrigued to see how this partnership unfolds—could it mean a new era of growth for Verimatrix? Definitely one to watch.
🧬 $SNGX - Promising Progress Against Behçet's Disease
Soligenix impressed with Phase 2 results for SGX945, aimed at treating Behçet's Disease. This rare and severe condition makes these advancements even more meaningful. Rare disease treatments often see fierce competition and lucrative markets. While there’s still a long road to approval, early signs look encouraging.
🌿 $PBM - Psyence Biomedical’s Psychedelic Potential
Psyence Biomedical, along with its partner PsyLabs, is making waves in psychedelics. With an industry growing rapidly and shifting public perception, $PBM could be positioned to ride this trend. There’s a speculative buzz around the company’s prospects, but as always with early-stage companies, stay cautious even amid excitement.
💊 $ENSC - A Game-Changer in Opioid Safety?
Ensysce Biosciences just received FDA feedback on its opioid product with built-in overdose protection. This is huge. An opioid with reduced risks could be a game-changer, both socially and commercially. The opioid crisis is a sensitive topic, but $ENSC seems set on tackling it with innovation.
🫁 $GRI - Biomarker Progress for a Deadly Disease
GRI Bio reported interim results for its Idiopathic Pulmonary Fibrosis study, and the insights could lead to new treatment pathways. IPF is a devastating condition, and this progress offers a glimmer of hope for patients. If the results hold steady, $GRI might have something powerful in the pipeline.
🧪 $SLXN - Fighting KRAS Mutations with New Preclinical Data
Silexion Therapeutics has made bold discoveries, claiming up to 97% inhibition of cancer cell growth. KRAS mutations are notoriously tough, and this data could mark a turning point. It’s early days, but this kind of innovation attracts attention from investors and larger pharmaceutical players alike.
💡 $TOVX - A Patent Win for Theriva Biologics
Theriva Biologics received patent approval for its intestinal alkaline phosphatase formulations. Not the flashiest of updates, but patent protection is key for long-term value. These building blocks can bolster confidence in $TOVX’s future.
🛒 $AMZN - Nearly Flawless Earnings Performance
Amazon just left analysts in the dust, reporting $1.68 per share in Q2—up 33% year-over-year. With $167.7 billion in sales, it seems the e-commerce titan is still flexing its muscles. $AMZN remains a juggernaut, and long-term investors must be smiling right now. If only all earnings reads were this sweet!
💵 $CETX - Cemtrex Dives into Crypto Investing
Cemtrex is banking hard on Solana, acquiring $1 million worth. They’re also targeting a $10 million crypto reserve, which feels like a bold and risky move. Cryptocurrencies are volatile, but $CETX clearly sees opportunity. Stay cautious here—crypto isn’t everyone’s cup of tea.
🩺 $FDMT - 4DMT’s Positive Clinical Results
4DMT delivered optimistic 60-week results for its SPECTRA trial targeting diabetic macular edema. Breakthroughs in vision-related treatments tend to be well-received, but investors should await regulatory clarity before getting too bullish.
What a packed day of updates! Biotech is buzzing, Amazon is crushing it, and a few smaller names are making bold moves. Remember, while some of these stocks have eye-catching developments, the road ahead might still hold surprises—good and bad. Dig deeper, diversify wisely, and always stay informed.
Catch you all in the Stock Region Telegram community! 🚀
Warm regards,
The Stock Region Team
Disclaimer: This newsletter is not financial advice. Stock investments come with risks, and readers should make decisions based on their individual financial circumstances.